Skip to content

VIMA

Active Private limited companyfounded 1999active for 27 yearsKruisstraat 57/A, 2500 LierKBO/BCE: BE 0465.441.632

Lifetime

19 annual accounts with figures on one time axis, 26 filings since 2000
peak of €191,127 in 2019
€117,133▲ 3.9%
peak of €126,146 in 2019
€79,702▲ 16.4%
peak of €672,647 in 2020
€472,529▼ 4.1%
€354,361▲ 29.1%
peak of 0 FTE in 2016
-not published
Board1 name since 1999
1 director
Documentsfilings and deeds
27-04-20263 days before the deadline
2025micro format
Dividend €100,000Debts from €274,525 to €354,361Investments €23,795Cash from €104,048 to €178,025

Key points

from the 2025 annual accounts

Equity

€472,529 ▼ 4.1%
492,8272024+79,702Profit-100,000Dividend472,5292025

VIMA paid out €100,000 in dividends. That is 125% of the 2025 profit.

Turnover

≈ €220,000 estimated

The micro format states no turnover.

Debts

€354,361 ▲ 29.1%
Other debts
+78,242
Taxes and wages
+4,935
The rest
-3,341

Debts rose by €79,837 in 2025. A dividend stands under other debts on the balance sheet date until it is paid.

Investments

€23,795 5.6 times depreciation
202320242025

Green is investment, beige is depreciation. Land and buildings stand 644.2% higher than in 2024.

Filings

26 annual accounts since 2000
deadline200020102020

The last five annual accounts were filed 3 to 24 days before the end of the period.

Position in the sector

€472,529

More equity than 81% of companies in human health. Sector median €125,088 · 21,349 companies.

Checked score

Bankruptcy probability within 12 months

Financial strength

Score breakdown

Comparable companies, two years later

In July 2024, 20,149 companies had the same profile as VIMA has now. Each dot stands for 51 companies, two years later.

95.0%
were still trading
4.7%
stopped another way
0.2%
went bankrupt
  • Small
  • 20 years or older
  • solvency 30% or more
  • a profit of 5% of the balance sheet or more
Test of the method

The method was tested on the 497,962 companies of July 2024. Each company was given the bankruptcy share of the same profile a year earlier, in July 2023. The expectation was that 1.6% would go bankrupt within 24 months. In fact 1.7% went bankrupt.

The companies in ten equal groups, from the lowest to the highest expected share
Group Expected Actual
1 0.2% 0.2%
2 0.3% 0.5%
3 0.5% 0.6%
4 0.7% 0.8%
5 0.9% 0.9%
6 1.3% 1.5%
7 1.6% 1.8%
8 1.8% 1.8%
9 2.9% 3.1%
10 5.6% 6.1%

A company that went bankrupt had a higher expected share than one that kept going in 74.5% of comparisons. The level depends on the economy. In a year with more bankruptcies than the year before, the actual share is higher than the expected one.

This is an observation about 20,149 companies, not a prediction for VIMA. The sector does not count, because the KBO no longer lists a sector for a company that has stopped. By sector, mostly the survivors would count, which would paint too rosy a picture.

Credit verdict

Credit check for an amount and term of your choice

Show the recommended maximum and see how the verdict changes with amount, term and advance.

The scores and ratios are Checked's own calculations, not a credit decision.

Signals

Board and ownership

Director
  • 10,507 sharesdeed of 07-07-2014
  • 0 sharesdeed of 07-07-2014
Board & ownership

Recent changes

Registered in the Peppol Directory Reachable for e-invoices through 0208:0465441632
appointed as director Gazette deed
Capital increase of €278,235 10,507 new shares · Capital contribution: Derde beslissing - inschrijving en volstorting · holds 10,507 shares · Gazette deed
Incorporation published on 23-02-1999 · Gazette deed
All 34 events

Comparable companies

same main activity, similar in size and age
Company
VIMA Lier €826,890 €117,133 57.1% -
MARIANNE PERSIJN Ghent €787,155 €122,352 98.5% -
MEDISCH KABINET DR. LUC MOENS Opwijk €841,102 €116,120 68.3% -
DR. EYCKEN MICHEL Temse €875,211 €103,696 68.0% -
DOKTER LYSSENS & VERCRUYSSE Lier €815,620 €98,338 97.8% -
DOKTER VERLINDEN ELS Mechelen €698,021 €116,900 47.6% -
DR HERSSENS HART-EN VAATZIEKTEN Puurs-Sint-Amands €883,774 €144,205 80.3% -

These companies have the same main activity as VIMA: specialist medical practice (NACE 86220). They are comparable in size and age: total assets between €698,000 and €884,000, founded between 1996 and 2004.

Official details

Source: KBO
Status
Active since 12-02-1999Normal situation
Activity
Specialist medical practiceNACE 86220
Establishment unit
2.270.649.6402500 Lier, since 12-02-1999
Financial year end
30 September
Peppol
Reachable since 21-10-2026
Company details

Annual accounts to 30-09-2025

€826,890▲ 7.8%
Filing
Filed on 27-04-2026, 3 days before the end of the filing period
Financials

Insights on VIMA

VIMA files the micro format. That format states no turnover. The gross margin rose from €60,698 in 2007 to €117,133 in 2025.

Sources: KBO register, filings at the National Bank, Belgian Official Gazette. Click a figure with a dotted line for the item and the filing.

Key facts about VIMA

What is the company number of VIMA?
The company number of VIMA is 0465.441.632. The VAT number is the same number with BE in front: BE 0465.441.632.
Where is VIMA based?
The registered office is at Kruisstraat 57/A, 2500 Lier.Company details
What does VIMA do?
According to the KBO register, the main activity is specialist medical practice (NACE 86220).
What is the legal form of VIMA?
VIMA is a private limited company (BV).
When was VIMA founded?
VIMA was founded on 12-02-1999.
Is VIMA still active?
Yes, VIMA is an active enterprise in the KBO register.
What is the turnover of VIMA?
The turnover in financial year 2025 is ≈ €220,000. This figure is estimated from the gross margin of €117,133 and 40 comparable companies (NACE 86220). It probably lies between €180,000 and €290,000.Financials
Is VIMA profitable?
In financial year 2025, VIMA made a profit of €79,702.
Where can I find the annual accounts of VIMA?
VIMA filed 26 annual accounts with the National Bank of Belgium, the latest for financial year 2025.
When are the next annual accounts of VIMA due?
VIMA must file the annual accounts for financial year 2026 by 30-04-2027.Timeline

Next steps

See how customers, suppliers and banks see your own company and what to improve first.

Keep this company with today's facts in a case file.